CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
This story comes from CNBC's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.